Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
Lloyd Paul Aiello, Robert L. Avery, Paul G. Arrigg, Bruce A. Keyt, Henry D. Jampel, Sabera T. Shah, Louis R. Pasquale, Hagen Thieme, Mami A. Iwamoto, John E. Park, Hung V. Nguyen, Lloyd M. Aiello, Napoleone Ferrara, and George L. King
Background Retinal ischemia induces intraocular neovascularization,which often leads to glaucoma, vitreous hemorrhage, and retinaldetachment, presumably by stimulating the release of angiogenicmolecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specificangiogenic factor whose production is increased by hypoxia.
Methods We measured the concentration of VEGF in 210 specimensof ocular fluid obtained from 164 patients undergoing intraocularsurgery, using both radioimmunoassays and radioreceptor assays.Vitreous proliferative potential was measured with in vitroassays of the growth of retinal endothelial cells and with VEGF-neutralizingantibody.
Results VEGF was detected in 69 of 136 ocular-fluid samplesfrom patients with diabetic retinopathy, 29 of 38 samples frompatients with neovascularization of the iris, and 3 of 4 samplesfrom patients with ischemic occlusion of the central retinalvein, as compared with 2 of 31 samples from patients with noneovascular disorders (P<0.001, P<0.001, and P = 0.006,respectively). The mean (±SD) VEGF concentration in 70samples of ocular fluid from patients with active proliferativediabetic retinopathy (3.6 ±6.3 ng per milliliter) washigher than that in 25 samples from patients with nonproliferativediabetic retinopathy (0.1 ±0.1 ng per milliliter, P =0.008), 41 samples from patients with quiescent proliferativediabetic retinopathy (0.2 ±0.6 ng per milliliter, P<0.001),or 31 samples from nondiabetic patients (0.1 ±0.2 ngper milliliter, P = 0.003). Concentrations of VEGF in vitreousfluid (8.8 ±9.9 ng per milliliter) were higher than thosein aqueous fluid (5.6 ±8.6 ng per milliliter, P = 0.033)in all 10 pairs of samples obtained simultaneously from thesame patient; VEGF concentrations in vitreous fluid declinedafter successful laser photocoagulation. VEGF stimulated thegrowth of retinal endothelial cells in vitro, as did vitreousfluid containing measurable VEGF. Stimulation was inhibitedby VEGF-neutralizing antibodies.
Conclusions Our data suggest that VEGF plays a major part inmediating active intraocular neovascularization in patientswith ischemic retinal diseases, such as diabetic retinopathyand retinal-vein occlusion.
Intraocular neovascularization occurs in numerous ischemic retinaldisorders, including diabetic retinopathy, ischemic retinal-veinocclusion, and retinopathy of prematurity1,2. This proliferationoften results in vitreous hemorrhage, retinal detachment, andneovascular glaucoma, with subsequent visual loss. Althoughnumerous growth factors stimulate angiogenesis in vivo,3,4,5,6these factors are not consistently increased in proliferativeretinopathies5,6 or secreted, as would be expected if they causedintraocular neovascularization at sites distant from those ofretinal ischemia.
In neovascular retinopathies such as proliferative diabeticretinopathy, there is initially extensive active proliferationof new vessels1,7. Visual loss at this time results from vitreoushemorrhage or fluid exudation from fragile new vessels. Withtime, or after laser photocoagulation, the proliferating vesselsbecome fibrotic and involute, causing traction on the retinathat may lead to complications such as retinal detachment8,9.Eventually the disease becomes inactive and further visual lossceases10. The timely inhibition of factors that cause activevascular proliferation may prevent visual loss.
To account for the clinical manifestations of neovascular diseaseinduced by ocular ischemia, it has been hypothesized that acausative substance is produced in the retina. The hypotheticalsubstance is induced by retinal ischemia and is angiogenic,diffusible, more concentrated in vitreous than in aqueous humor,increased during active proliferation, reduced during quiescentproliferation, and diminished after successful laser therapy.Vascular endothelial growth factor (VEGF) is a candidate forsuch a substance. It is an endothelial-cell-specific angiogenic11and vasopermeable12 factor that binds to high-affinity, membrane-boundreceptors with tyrosine kinase activity13,14. Its expressionis induced by hypoxia in tumors12,15,16,17. VEGF is secretedin four homodimeric forms resulting from alternative RNA splicing18.In ocular tissues its production is increased by hypoxia inretinal pigment epithelial cells19 and retinal pericytes,20,21and by ischemia-induced neovascularization of the iris in primateeyes22. In our study we attempted to ascertain whether intraocularconcentrations of VEGF correlated with active neovascularizationand to determine whether VEGF fulfilled the other criteria23hypothesized for an angiogenic factor in ischemic ocular disorders.
Methods
Study Subjects
Undiluted samples of aqueous, vitreous, and subretinal fluidwere obtained from patients undergoing intraocular surgery.The protocol for sample collection was approved by the institutionalreview board at each institution, and all patients gave informedconsent. The surgical procedures included cataract extraction,trabeculectomy, anterior-chamber paracentesis, pars plana vitrectomy,scleral buckling, and pneumatic retinopexy. The patients' primarydiagnoses included cataract, chronic open-angle glaucoma, traumaticglaucoma, phacolytic glaucoma, proliferative diabetic retinopathy,neovascular glaucoma, stage 5 retinopathy of prematurity, ischemiccentral-retinal-vein occlusion, vitreous hemorrhage, tractionor rhegmatogenous retinal detachment, macular pucker, endophthalmitis,leukemic retinopathy, epiretinal membrane, choroidal neovascularmembrane, uveitis, and retinitis.
Clinical data, including determinations of ocular neovascularactivity, were obtained from the surgeon at the time of surgerywith standardized forms and were confirmed by standardized fundusphotography whenever possible. Neovascularization was consideredto be active if there were perfused, multibranching iridic orpreretinal capillaries (Figure 1A) and to be quiescent if previouslydocumented active proliferation had regressed fully or if onlynonperfused, gliotic vessels or fibrosis was present (Figure 1B).
Figure 1. Classification of Active and Quiescent Intraocular Neovascularization.
Panel A shows typical active neovascularization as defined in the Methods section (vitreous VEGF concentration, 1.9 ng per milliliter). There is extensive retinal neovascularization (black arrows) arising from the optic-nerve head, vitreous hemorrhage (white arrow), and scarring from panretinal laser photocoagulation (arrowhead). Panel B shows quiescent neovascularization with no detectable vitreous VEGF concentration. There are numerous nonperfused, gliotic vessel remnants (arrows).
The results in patients with retinal neovascularization werecompared with those in patients with the same underlying disordersbut no retinal neovascularization and with those in patientswith no known underlying potentially neovascularizing disorder.We therefore excluded from this group patients with diabetesmellitus, rubeosis iridis, retinal detachment, choroidal neovascularmembranes, retinopathy of prematurity, central-retinal-veinocclusion, uveitis, and retinitis. The indications for surgeryin the control group included cataract, chronic open-angle glaucoma,angle-recession glaucoma, and idiopathic epiretinal membrane.
Sample Collection
The samples of ocular fluid were collected in sterile tubes(Thomas Scientific, Swedesboro, N.J.), placed immediately onice, clarified by centrifugation at 16,000 x g for five minutesat 4 °C, and rapidly frozen at -80 °C. The samples wereshipped by overnight mail in dry ice with accompanying dataon the patient to the Joslin Diabetes Center, where they werecatalogued and labeled in an anonymous fashion. The specimenswere then shipped without identifying clinical information toGenentech for the VEGF immunologic and receptor-binding assays.
Radioimmunoassay
Concentrations of VEGF in ocular fluid were measured by radioimmunometricassay with two monoclonal antibodies that bound to differentepitopes on VEGF165 and longer isoforms24. The assays were performedin 96-well immunoplates (Immunlon-1, Dynatech, Chantilly, Va.);each well was coated with 100 microl of a solution containing10 µg of anti-VEGF monoclonal antibody 5F8 (similar toantibody B2.6.224) per milliliter of solution in 50-mM carbonatebuffer (pH 9.6) for 16 hours at 4 °C. The plates were washedthree times, blocked for one hour at 25 °C with 300 microlof 0.5 percent bovine serum albumin and 0.03 percent Tween 80in phosphate-buffered saline (pH 7.4) per well, and washed subsequentlywith 0.03 percent Tween 80 in phosphate-buffered saline (pH7.4) before the addition of diluted samples of ocular fluid(in duplicate measurements of three to six serial twofold dilutions)or standard solutions of VEGF165 (range, 20 pg per milliliterto 50 µg per milliliter).
The plates were incubated for two hours at 25 °C with gentleagitation, the supernatants were discarded, and the wells washed.One hundred microls of a solution containing 2 x 104 cpm of125I-labeled anti-VEGF165 monoclonal antibody 2E3 (similar toantibody A4.6.124) was added, and the plates were incubatedfor two hours at 25 °C with gentle agitation. The supernatantswere discarded, the plates washed, and the wells counted bygamma scintigraphy (LKB gamma counter, Gaithersburg, Md.). Concentrationsof VEGF were quantitated from a standard curve for VEGF witha four-parameter fit (Kaleidagraph, Synergy Software, Reading,Pa.). The sensitivity of the assay was 0.05 ng per milliliter.The intraassay and interassay coefficients of variation were5 and 6 percent, respectively. Ocular-fluid samples with undetectableVEGF concentrations in this assay or the receptor-binding assay(described below) were assigned values of 0.05 ng per milliliter.
Receptor-Binding Assay
The procedure for the receptor-binding assay was similar tothat used in the radioimmunoassay, except that 125I-labeledfms-like tyrosine kinase (Flt-1) receptor-IgG chimeric proteinwas used instead of 125I-labeled anti-VEGF monoclonal antibody2E3. The 5F8 monoclonal anti-VEGF antibody used to coat theplates does not interfere with ligand-receptor binding. Flt-1is a high-affinity VEGF receptor25. Its entire extracellulardomain (758 residues) was cloned by the polymerase chain reactionwith Pfu polymerase and fused to the coding sequence for aminoacids 216 through 443 of an IgG1 heavy-chain clone,26 as describedby Park et al27. The chimeric receptor has the same affinityfor VEGF as does the full-length VEGF receptor. The sensitivityand variability of this assay were similar to those of the radioimmunoassay.
Assay of Retinal Vascular Endothelial-Cell Growth
Bovine endothelial cells from the retinal microvasculature wereisolated by homogenization and a series of filtration stepsas described elsewhere28. Primary cultures were grown in fibronectin-coateddishes (NYBen Reagents, New York Blood Center, New York) containingDulbecco's modified Eagle's medium with 5.5 mM glucose, 10 percenthorse serum (Wheaton, Pipersville, Pa.), 50 mg of heparin perliter, and 50 units of endothelial-cell growth factor per liter(Boehringer Mannheim, Indianapolis). After the cultures wereconfluent, the medium was changed to include 5 percent fetal-calfserum (Hyclone, South, Utah). The cells were fed every threedays. Endothelial-cell homogeneity was confirmed with anti-factorVIII antibodies. For the assay, the cells were plated sparsely(2500 cells per well) in 24-well dishes (Costar, Cambridge,Mass.) and incubated overnight in Dulbecco's modified Eagle'smedium containing 10 percent calf serum (GIBCO, Grand Island,N.Y.). The mediums were changed the next day, and either VEGFor vitreous fluid (final volume, 15 to 25 percent) was added,with either phosphate-buffered saline or a 1- to 10-fold excessof VEGF-neutralizing rabbit polyclonal antibody. After incubationat 37 °C for four days, the cells were lysed in 0.1 percentsodium dodecyl sulfate, and the DNA content was measured withdye (Hoechst 33258, Hoefer Scientific Instruments, San Francisco)and a fluorometer (model TKO-100, Hoefer). A statistically significantgrowth response could be detected at concentrations of VEGFas low as 0.1 ng per milliliter. The plates were assayed intriplicate, and each experiment was repeated at least threetimes unless otherwise indicated.
Statistical Analysis
Categorical data were compared by Fisher's exact test. The unpairedStudent's t-test was used to compare quantitative data withnormal distributions. Log-normal transformed data were analyzedby the paired t-test for comparisons with unequal variance beforeand after laser treatment. Immunoreactivity and receptor-bindingcorrelations were determined with linear regression analysis(sum of squares), and significance was calculated from the mean-squareF ratio. Ocular-gradient results were analyzed with the pairedStudent's t-test. Values are reported as means ±SD. Two-tailedtest results were considered statistically significant at P 0.05.
Results
We obtained 210 samples of ocular fluid from 171 eyes of 164patients (88 women and 76 men) undergoing intraocular surgery.Sixty-five percent of the patients were white, 15 percent wereblack, 5 percent were Hispanic, and 15 percent were of otheror undetermined descent. The mean age of the 31 patients withno known neovascular disorders was 64 years (range, 10 to 89),and the mean age of the 113 patients with proliferative diseaseswas 57 years (range, 5 months to 89 years). These groups didnot differ with regard to sex or ethnic background. The meanages of the patients with nonproliferative and proliferativediabetic retinopathy were 69 and 53 years, respectively, butthere was no difference in mean age among the patients withactive proliferative diabetic retinopathy, quiescent proliferativediabetic retinopathy, or neovascularization of the iris (51,55, and 51 years, respectively). The patients with no neovasculardisorders and those with nonproliferative diabetic retinopathywere slightly older than those with proliferative diabetic retinopathyor neovascularization of the iris, probably because the firsttwo of these groups primarily undergo surgery for conditions(e.g., cataract) associated with advancing age. Only two patientswith neovascularization had not received retinal laser photocoagulationbefore the collection of ocular fluids. There was no correlationof VEGF concentrations with age, sex, or ethnic background inany subgroup.
Detection of VEGF in Ocular Fluid
The number and percentage of samples of aqueous and vitreousfluid with detectable concentrations of immunoreactive VEGFare shown in Table 1; results for subretinal-fluid samples arepresented in a footnote to Table 1. VEGF was detected in 2 of31 samples from patients with no neovascular disorder, 69 of136 samples from patients with diabetes mellitus, 29 of 38 samplesfrom patients with neovascularization of the iris, 5 of 9 samplesfrom patients with chronic retinal detachment, and 3 of 4 samplesfrom patients with central-retinal-vein occlusion. Among patientswith diabetes mellitus, VEGF was detectable in 58 of 70 samplesfrom patients with active proliferative retinopathy, as comparedwith 9 of 41 samples from patients with quiescent proliferativeretinopathy and 2 of 25 samples from patients with nonproliferativediabetic retinopathy. VEGF was detected in similar proportionsin both aqueous and vitreous fluids among the various groupsof patients. It was not detected in any sample collected frompatients with endophthalmitis, leukemic retinopathy, uveitis,retinitis, epiretinal membrane, or choroidal neovascular membrane.VEGF was detected in 47 percent of 68 patients with retinaldetachment, although 39 had concurrent proliferative diabeticretinopathy. When patients with diabetes mellitus were excluded,VEGF was detected in 5 of 9 samples from patients with chronicretinal detachment (i.e., lasting more than three weeks), ascompared with 1 of 31 samples from patients without neovasculardisorders (P = 0.003). Mean concentrations of VEGF were higherin samples from patients with chronic retinal detachment (2.8±4.7 ng per milliliter) than patients with acute retinaldetachment (0.1 ±0.1 ng per milliliter, P = 0.024).
Table 1. Concentrations of Immunoreactive VEGF in Ocular Fluids of Patients with Retinal Disorders.
VEGF Concentrations and Ocular Neovascularization
The VEGF concentrations in samples of aqueous and vitreous humorfrom patients without neovascular disorders were compared withthose in samples from patients with active or quiescent neovascularization(Figure 2). VEGF was detectable in only 13 of 96 samples frompatients with no active neovascularization (mean, 0.1 ±0.4ng per milliliter), and when detectable, the concentrationswere low (0.7 ±0.9 ng per milliliter). The mean VEGFconcentration in 70 samples from patients with active proliferativediabetic retinopathy (3.6 ±6.3 ng per milliliter) wassignificantly higher than that in 31 samples from nondiabeticpatients with no proliferative disorder (0.1 ±0.2 ngper milliliter, P = 0.003) and that in 41 samples from patientswith quiescent proliferative diabetic retinopathy (0.2 ±0.6ng per milliliter, P<0.001). The concentrations of VEGF werealso high in samples from patients with active proliferationfrom ischemic central-retinal-vein occlusion, retinopathy ofprematurity, or rubeosis iridis. The concentrations were similarwhen samples of aqueous and vitreous humor were considered individually(Table 2).
Figure 2. Concentrations of Immunoreactive VEGF in Ocular Fluids from Patients Undergoing Intraocular Surgery.
Aqueous (squares), vitreous (diamonds), and mean (arrowheads) VEGF concentrations are shown. Values of zero or below on the y axis denote concentrations below 0.05 ng per milliliter. PDR denotes proliferative diabetic retinopathy, and CRVO central-retinal-vein occlusion.
Table 2. Concentrations of Immunoreactive VEGF in Aqueous and Vitreous Fluids.
Determination of Intraocular Gradient of VEGF
Simultaneously collected samples of fluid from the anteriorsegment (aqueous humor) and the posterior segment (either vitreoushumor or subretinal fluid) were tested for VEGF in 14 patients,10 of whom had active ocular neovascularization and detectableVEGF in the posterior segment. In each of these patients, theposterior-segment VEGF concentration exceeded the aqueous concentration.The mean posterior-segment VEGF concentration was almost 60percent higher (8.8 ±9.9 vs. 5.6 ±8.6 ng per milliliter,P = 0.033).
Response of VEGF after Treatment of Ocular Neovascularization
Collecting ocular fluids before and after treatment for neovascularizationis difficult, because patients who undergo surgery rarely requiresubsequent procedures. We studied six patients with active neovascularizationand one patient with quiescent neovascularization, from eachof whom two samples of ocular fluid were collected. The subsequentprocedures involved were trabeculectomy (one patient), secondvitrectomy (five patients), and anterior-chamber paracentesis(one patient). All the patients had also undergone panretinallaser photocoagulation for neovascularization in the intervalbetween the two operations, and the extent of proliferationhad decreased. The intraocular concentrations of VEGF were reducedby an average of 75 percent (from 5.6 ±6.5 to 1.4 ±2.0ng per milliliter, P = 0.008) in all the patients after successfultreatment.
Receptor-Binding Capacity of Ocular VEGF
Among the 19 vitreous-fluid samples randomly tested, all 16samples with detectable immunoreactive VEGF also had receptor-bindingactivity, as compared with none of the 3 samples without detectableimmunoreactive VEGF. The receptor-binding concentration was45 percent of the immunoreactivity concentration, and the correlationbetween the two types of activity was statistically significant(R2 = 0.93, P<0.001).
Stimulation of Retinal Vascular Endothelial-Cell Growth by Ocular VEGF
The number of retinal endothelial cells was increased in vitroin a dose-dependent manner after exposure to 5 or 10 ng of VEGFper milliliter. VEGFneutralizing antibodies blocked this stimulatoryeffect (Figure 3). The maximally effective VEGF concentrationwas 25 ng per milliliter, and the half-maximally effective concentrationwas 1 ng per milliliter (data not shown).
Figure 3. Growth of Retinal Endothelial Cells in Response to VEGF.
Recombinant human VEGF was added to triplicate cultures of bovine retinal endothelial cells in the presence of a fourfold excess of VEGF-neutralizing antibodies, as shown. Growth stimulation was assessed after four days by measuring the total cellular DNA content. Plus and minus signs indicate that antibody was used and not used, respectively. Values are expressed as means ±SD. NS denotes not significant.
To determine whether VEGF in human vitreous was bioactive, theendothelial proliferative activity of pooled samples of vitreoushumor from five patients with active proliferative diabeticretinopathy, a single patient with active proliferative diabeticretinopathy, and pooled samples from six patients with quiescentproliferative diabetic retinopathy was measured. The concentrationsof VEGF in these samples were 4.0, 3.3, and <0.05 ng permilliliter, respectively. All the samples stimulated retinalendothelial-cell growth (Figure 4). The addition of VEGF-neutralizingantibody did not significantly reduce the response to vitreousfluid from patients with quiescent retinopathy, but it inhibitedby 65 percent the response to vitreous fluid from patients withactive proliferative diabetic retinopathy.
Figure 4. Growth of Retinal Endothelial Cells in Response to VEGF in Vitreous Fluid.
Control samples of phosphate-buffered saline (bars 1 and 2) or vitreous-fluid samples from patients with quiescent (bars 3 and 4) or active (bars 5, 6, 7, and 8) neovascularization were added to cultures of retinal endothelial cells (final volume, 25 percent). The samples used in bars 3 and 4 were pooled from six patients, those used in bars 7 and 8 were pooled from five patients, and that used in bars 5 and 6 was from a single patient. VEGF-neutralizing antibody was added to the cultures shown in the even-numbered bars, and phosphate-buffered saline to the remaining cultures. The maximal VEGF-neutralizing capacity of the antibody was either 5.0 ng per milliliter (bars 2, 4, and 8) or 50 ng per milliliter (bar 6). Growth stimulation was assessed after four days by measuring the total cellular DNA content. The results are expressed as mean (±SD) percentages of the control value (bar 1) for triplicate wells obtained in either multiple experiments (bars 1, 2, 3, 4, 7, and 8) or a single experiment (bars 5 and 6). NS denotes not significant.
Discussion
We found detectable concentrations of VEGF in ocular fluid frompatients with active retinal and anterior-segment neovascularizationassociated with several ocular diseases with underlying retinalischemia. In the patients with active neovascularization, VEGFconcentrations in the aqueous and vitreous fluid were higherthan those that have stimulated endothelial-cell proliferationin vitro and in vivo22. In patients with quiescent neovascularizationresulting from retinopathy of prematurity, central-retinal-veinocclusion, or diabetes mellitus, concentrations of VEGF werelow or undetectable.
The clinical observation that anterior-segment neovascularizationcommonly arises in conjunction with ischemic retinal diseasesuggests a gradient-driven diffusion of angiogenic factors fromthe posterior to the anterior segment of the eye. Among allthe samples, concentrations of VEGF were higher in aqueous thanin vitreous fluid, but in simultaneously collected samples theconcentrations of VEGF in vitreous fluid were always higher.This gradient may result from the rapid clearance of VEGF fromthe anterior chamber or from its increased use or more rapiddegradation in that chamber. Nevertheless, a vitreous-to-aqueousgradient would promote the anterior diffusion of VEGF, potentiallyaccounting for the clinically observed anterior-segment neovascularizationassociated with retinal ischemia.
Panretinal photocoagulation induces the regression of clinicallyactive ocular neovascularization8,9. We found that concentrationsof VEGF declined in all patients who had decreased neovascularactivity after laser photocoagulation. Presumably, the reductionin retinal ischemia after laser therapy reduces the productionof angiogenic factors, suppressing neovascularization. Indeed,ischemia-induced VEGF production is reversible by the reinstitutionof a normal oxygen supply in vitro21,29.
Vitreous fluid from patients without active retinal neovascularizationstimulated the growth of retinal endothelial cells, as haveretinal extracts from normal eyes30. In samples of vitreousfrom patients with active proliferative diabetic retinopathyand high concentrations of VEGF, anti-VEGF antibodies reducedin vitro stimulation of growth by more than 65 percent, to valuessimilar to those in samples from patients with quiescent neovascularizationand undetectable concentrations of VEGF. The incomplete inhibitionof growth-stimulatory activity suggests the simultaneous activityof other proliferative factors. Indeed, vitreous concentrationsof basic fibroblast growth factor,31 insulin-like growth factors,and insulin-like growth factor-binding proteins are increasedin patients with diabetic retinopathy and rubeosis iridis5.
VEGF is present in the ocular membranes of patients with proliferativediabetic retinopathy,32 hypoxia stimulates the secretion ofVEGF in retinal pigment epithelial cells,29 and VEGF productionincreases with neovascularization of the iris in primates22.We have reported that retinal endothelial cells have large numbersof high-affinity VEGF receptors14 and that hypoxia increasesthe VEGF content of messenger RNA (mRNA) in retinal pericytes,retinal endothelial cells, and retinal pigment epithelial cells-- an effect reversed by the reinstitution of normal oxygenation21.These observations suggest a plausible scenario for the initiationand control of the ischemic ocular neovascular response. Alterationsin retinal perfusion arising from decreased blood flow (e.g.,central-retinal-vein occlusion or carotid occlusive disease33,34,35),retinal-capillary loss (resulting from diabetic retinopathyor radiation retinopathy, for example), peripheral-vasculatureagenesis or obliteration (with, e.g., retinopathy of prematurityor sickle cell disease), or separation of the choroidal bloodsupply from the retinal pigment epithelium (with, e.g., retinaldetachment) can all result in relative retinal ischemia. Thisischemia stimulates the synthesis and secretion of VEGF in retinalpericytes, endothelial cells, the retinal pigment epithelium,and possibly other cell types. Depending on the particular variantof mRNA splicing,18 secreted VEGF is either bound to cell-surfaceor basement-membrane proteoglycans containing heparin (VEGF189,286)or is freely diffusible within the vitreous cavity (VEGF121,165)36.Diffusible VEGF follows its concentration gradient from thevitreous to the anterior segment and is ultimately cleared throughthe trabecular meshwork. Neovascularization induced by the directaction of VEGF on endothelial cells can arise anywhere alongthis course, especially in areas of high exposure, such as thepupillary border and the trabecular meshwork. The angiogenicpotential of VEGF is enhanced by the synergistic activity offibroblast growth factor liberated by cellular disruption ordeath4,37,38. Cell death without ischemia would have less vasoproliferativepotential, since increased VEGF production would not be possible.Indeed, the risk of ocular neovascularization in anoxic retinaldisorders, such as retinal-artery occlusion, is lower than inischemic diseases, such as retinal-vein occlusion33. The reductionin relative retinal ischemia as a result of reperfusion, laserphotocoagulation, or extensive cell death may reduce the productionof VEGF and result in neovascular regression and quiescence.
VEGF meets the criteria hypothesized for an ischemia-inducedocular angiogenic factor,23 and we suggest that it has an importantrole in mediating the neovascular response of diabetic retinopathyand other ischemic retinal disorders. Deciphering the mechanismsunderlying the expression of hypoxia-induced VEGF and its biologiceffects should increase our understanding of numerous ocularneovascular diseases and provide new therapeutic approachesto preserving vision.
Supported in part by a grant (EY05110) (to Dr. King) and a pilotand feasibility grant (DERC36836-08) (to Dr. L.P. Aiello), bothfrom the National Institutes of Health; a Capps Scholarshipin Diabetes (to Dr. L.P. Aiello); a Heed/Knapp Fellowship fromthe Heed Ophthalmic Foundation (to Dr. L.P. Aiello); and a Diabetesand Endocrinology Research Center Grant (36836) from the NationalInstitutes of Health (to the Joslin Diabetes Center).
We are indebted to Ms. Leslie Balmat, Sven E. Bursell, Ph.D.,Peter A. Campochiaro, M.D., Jerry D. Cavallerano, O.D., Ph.D.,Leo T. Chylack, M.D., Eugene DeJuan, M.D., Mr. Dennis Fleming,Julia A. Haller, M.D., Jin Kim, Ph.D., Ms. Kimberly Keville,Mr. Ji Lu, Jeffrey Luttrull, M.D., and Pearl Yazbek, R.N., fortheir assistance in the acquisition of samples, the productionof antibody, and the preparation of the manuscript.
Source Information
From the Department of Ophthalmology, Beetham Eye Institute (L.P.A., P.G.A., S.T.S., L.M.A.), and the Division of Research (L.P.A., H.T., G.L.K.), Joslin Diabetes Center; the Departments of Medicine and Ophthalmology, Brigham and Women's Hospital (L.R.P., M.A.I., G.L.K.); and Harvard Medical School (L.P.A., P.G.A., S.T.S., L.R.P., H.T., M.A.I., L.M.A., G.L.K.) -- all in Boston; the Neuroscience Research Institute, University of California, Santa Barbara (R.L.A.); Genentech, Inc., San Francisco (B.A.K., J.E.P., H.V.N., N.F.); and the Department of Ophthalmology, Wilmer Ophthalmological Institute, Johns Hopkins Hospital, Baltimore (H.D.J.).
Address reprint requests to Dr. L.P. Aiello at the Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215.
References
White P. Childhood diabetes: its course, and influence on the second and third generations. Diabetes 1960;9:345-355.
Patz A. Studies on retinal neovascularization. Invest Ophthalmol Vis Sci 1980;19:1133-1138. [Free Full Text]
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985. [Free Full Text]
Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A 1987;84:2292-2296. [Free Full Text]
Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. J Clin Invest 1993;92:2620-2625.
Hanneken A, de Juan E Jr, Lutty GA, Fox GM, Schiffer S, Hjelmeland LM. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol 1991;109:1005-1011. [Free Full Text]
Rand LI. Recent advances in diabetic retinopathy. Am J Med 1981;70:595-602. [CrossRef][Medline]
The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-396. [Medline]
Early Treatment Diabetic Retinopathy Study Research Group. Results from the Early Treatment Diabetic Retinopathy Study. Ophthalmology 1991;98:Suppl:741-840. [Medline]
Blankenship GW. Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology 1991;98:125-128. [Medline]
Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32. [Free Full Text]
Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-5632. [Free Full Text]
Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992;89:244-253.
Thieme H, Aiello LP, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor (VEGF) receptors on retinal and aortic microvascular endothelial cells. Diabetes (in press).
Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-844. [CrossRef][Medline]
Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845. [CrossRef][Medline]
Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848. [CrossRef][Medline]
Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-11954. [Free Full Text]
Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993;193:631-638. [CrossRef][Medline]
Plouet J, Chollet P, Moro F, Malecaze F. Secretion of VAS/VEGF by retinal pericytes: a paracrine stimulation of endothelial cell proliferation. Invest Ophthalmol Vis Sci 1993;34:900-900.abstract
Aiello LP, Ferrara N, King GL. Hypoxic regulation and bioactivity of vascular endothelial growth factor: characterization in retinal microvascular pericytes and pigment epithelial cells. Invest Ophthalmol Vis Sci 1994;35:1868-1868.abstract
Adamis AP, Miller JW, O'Reilly M, et al. Vascular permeability factor (vascular endothelial growth factor) is produced in the retina and elevated levels are present in the aqueous humor of eyes with iris neovascularization. Invest Ophthalmol Vis Sci 1993;34:1440-1440.abstract
Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc U K 1948;68:137-180.
Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64. [Medline]
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-991. [Free Full Text]
Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989;337:525-531. [CrossRef][Medline]
Park JE, Chen HH, Winer J, Houck K, Ferrara N. Placenta growth factor: potentiation of vascular endothelial growth factor activity, in vivo and in vitro, and high affinity binding to Flt-1 but not KDR. J Biol Chem 1994;269:25646-25654. [Free Full Text]
King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985;75:1028-1036.
Shima D, Adamis AP, Yeo KT, Yeo TK, Berse B, Brown L. Hypoxic regulation of vascular permeability factor (vascular endothelial growth factor) mRNA and protein secretion by human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1993;34:900-900.abstract
Glaser BM, D'Amore PA, Michels RG, Patz A, Fenselau A. Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol 1980;84:298-304. [Free Full Text]
Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1990;108:869-872. [Free Full Text]
Malecaze F, Clamens S, Mathis A, et al. Expression of angiogenic growth factors in diabetic neovascular membranes. Invest Ophthalmol Vis Sci 1993;34:1039-1039.abstract
Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF. Ocular neovascularization with retinal vascular occlusion. III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983;90:488-506. [Medline]
Brown GC, Magargal LE. The ocular ischemic syndrome: clinical fluorescein angiographic and carotid angiographic features. Int Ophthalmol 1988;11:239-251. [CrossRef][Medline]
Brown GC. The ocular ischemic syndrome. In: Ryan SJ, ed. Retina. Vol. 2. Medical retina. St. Louis: C.V. Mosby, 1989:547-59.
Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267:26031-26037. [Free Full Text]
Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-831. [CrossRef][Medline]
Muthukrishnan L, Warder E, McNeil PL. Basic fibroblast growth factor is efficiently released from a cytolsolic storage site through plasma membrane disruptions of endothelial cells. J Cell Physiol 1991;148:1-16. [CrossRef][Medline]
Li, Z., Van Bergen, T., Van de Veire, S., Van de Vel, I., Moreau, H., Dewerchin, M., Maudgal, P. C., Zeyen, T., Spileers, W., Moons, L., Stalmans, I.
(2009). Inhibition of Vascular Endothelial Growth Factor Reduces Scar Formation after Glaucoma Filtration Surgery. IOVS
50: 5217-5225
[Abstract][Full Text]
Zhao, H., Jin, H., Li, Q., Gu, Q., Zheng, Z., Wu, H., Ye, S., Sun, X., Xu, X., Ho, P. C. P.
(2009). Inhibition of Pathologic Retinal Neovascularization by a Small Peptide Derived from Human Apolipoprotein(a). IOVS
50: 5384-5395
[Abstract][Full Text]
Chew, E. Y.
(2009). Laser Photocoagulation and Intravitreal Injection of Triamcinolone for Retinal Vein Occlusions. JAMA
302: 1693-1695
[Full Text]
Clapp, C., Thebault, S., Jeziorski, M. C., Martinez De La Escalera, G.
(2009). Peptide Hormone Regulation of Angiogenesis. Physiol. Rev.
89: 1177-1215
[Abstract][Full Text]
Sakurai, K., Akiyama, H., Shimoda, Y., Yoshida, I., Kurabayashi, M., Kishi, S.
(2009). Effect of Intravitreal Injection of High-Dose Bevacizumab in Monkey Eyes. IOVS
50: 4905-4916
[Abstract][Full Text]
Basu, A., Menicucci, G., Maestas, J., Das, A., McGuire, P.
(2009). Plasminogen Activator Inhibitor-1 (PAI-1) Facilitates Retinal Angiogenesis in a Model of Oxygen-Induced Retinopathy. IOVS
50: 4974-4981
[Abstract][Full Text]
Abhary, S., Hewitt, A. W., Burdon, K. P., Craig, J. E.
(2009). A Systematic Meta-Analysis of Genetic Association Studies for Diabetic Retinopathy. Diabetes
58: 2137-2147
[Abstract][Full Text]
Kinnunen, K, Puustjarvi, T, Terasvirta, M, Nurmenniemi, P, Heikura, T, Laidinen, S, Paavonen, T, Uusitalo, H, Yla-Herttuala, S
(2009). Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes. Br J Ophthalmol
93: 1109-1115
[Abstract][Full Text]
Welch, D E, Elmariah, H, Peden, M C, Adams, S G, Ratnakaram, R, Kaushal, S
(2009). Short-term response of macular oedema to intravitreal bevacizumab. Br J Ophthalmol
93: 1033-1036
[Abstract][Full Text]
Murakami, T., Felinski, E. A., Antonetti, D. A.
(2009). Occludin Phosphorylation and Ubiquitination Regulate Tight Junction Trafficking and Vascular Endothelial Growth Factor-induced Permeability. J. Biol. Chem.
284: 21036-21046
[Abstract][Full Text]
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., Klein, R.
(2009). Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. NEJM
361: 40-51
[Abstract][Full Text]
Satofuka, S., Ichihara, A., Nagai, N., Noda, K., Ozawa, Y., Fukamizu, A., Tsubota, K., Itoh, H., Oike, Y., Ishida, S.
(2009). (Pro)renin Receptor-Mediated Signal Transduction and Tissue Renin-Angiotensin System Contribute to Diabetes-Induced Retinal Inflammation. Diabetes
58: 1625-1633
[Abstract][Full Text]
Shimada, H., Akaza, E., Yuzawa, M., Kawashima, M.
(2009). Concentration Gradient of Vascular Endothelial Growth Factor in the Vitreous of Eyes with Diabetic Macular Edema. IOVS
50: 2953-2955
[Abstract][Full Text]
Yang, L.-p., Sun, H.-l., Wu, L.-m., Guo, X.-j., Dou, H.-l., Tso, M. O. M., Zhao, L., Li, S.-m.
(2009). Baicalein Reduces Inflammatory Process in a Rodent Model of Diabetic Retinopathy. IOVS
50: 2319-2327
[Abstract][Full Text]
Prager, F, Michels, S, Kriechbaum, K, Georgopoulos, M, Funk, M, Geitzenauer, W, Polak, K, Schmidt-Erfurth, U
(2009). Intravitreal bevacizumab (Avastin(R)) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol
93: 452-456
[Abstract][Full Text]
Funk, M., Kriechbaum, K., Prager, F., Benesch, T., Georgopoulos, M., Zlabinger, G. J., Schmidt-Erfurth, U.
(2009). Intraocular Concentrations of Growth Factors and Cytokines in Retinal Vein Occlusion and the Effect of Therapy with Bevacizumab. IOVS
50: 1025-1032
[Abstract][Full Text]
Chung, T.-W., Kim, S.-J., Choi, H.-J., Kim, K.-J., Kim, M.-J., Kim, S.-H., Lee, H.-J., Ko, J.-H., Lee, Y.-C., Suzuki, A., Kim, C.-H.
(2009). Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2. Glycobiology
19: 229-239
[Abstract][Full Text]
Radi, Z. A.
(2009). Pathophysiology of Cyclooxygenase Inhibition in Animal Models. Toxicol Pathol
37: 34-46
[Abstract][Full Text]
Brunner, S., Schernthaner, G.-H., Satler, M., Elhenicky, M., Hoellerl, F., Schmid-Kubista, K. E., Zeiler, F., Binder, S., Schernthaner, G.
(2009). Correlation of Different Circulating Endothelial Progenitor Cells to Stages of Diabetic Retinopathy: First In Vivo Data. IOVS
50: 392-398
[Abstract][Full Text]
Smith, L. E. H.
(2008). Through The Eyes of a Child: Understanding Retinopathy through ROP The Friedenwald Lecture. IOVS
49: 5177-5182
[Full Text]
Huang, Q., Sheibani, N.
(2008). High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am. J. Physiol. Cell Physiol.
295: C1647-C1657
[Abstract][Full Text]
Cohen, M. P., Hud, E., Wu, V.-Y., Shearman, C. W.
(2008). Amelioration of Diabetes-Associated Abnormalities in the Vitreous Fluid by an Inhibitor of Albumin Glycation. IOVS
49: 5089-5093
[Abstract][Full Text]
Sears, J. E
(2008). Anti-vascular endothelial growth factor and retinopathy of prematurity. Br J Ophthalmol
92: 1437-1438
[Full Text]
Hata, Y, Sassa, Y, Kita, T, Miura, M, Kano, K, Kawahara, S, Arita, R, Nakao, S, Shih, J L, Ishibashi, T
(2008). Vascular endothelial growth factor expression by hyalocytes and its regulation by glucocorticoid. Br J Ophthalmol
92: 1540-1544
[Abstract][Full Text]
Krediet, R. T., Zweers, M. M., van Westrhenen, R., Zegwaard, A., Struijk, D. G.
(2008). Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?. NDT Plus
1: iv56-iv62
[Abstract][Full Text]
Yamaji, Y., Yoshida, S., Ishikawa, K., Sengoku, A., Sato, K., Yoshida, A., Kuwahara, R., Ohuchida, K., Oki, E., Enaida, H., Fujisawa, K., Kono, T., Ishibashi, T.
(2008). TEM7 (PLXDC1) in Neovascular Endothelial Cells of Fibrovascular Membranes from Patients with Proliferative Diabetic Retinopathy. IOVS
49: 3151-3157
[Abstract][Full Text]
Vieitez, P., Gomez, O., Uceda, E. R, Vera, M. E., Molina-Holgado, E.
(2008). Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. Journal of Renin-Angiotensin-Aldosterone System
9: 96-102
[Abstract]
Shen, L. Q., Child, A., Weber, G. M., Folkman, J., Aiello, L. P.
(2008). Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy. Arch Ophthalmol
126: 793-799
[Abstract][Full Text]
Deissler, H, Deissler, H, Lang, S, Lang, G E
(2008). VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol
92: 839-843
[Abstract][Full Text]
Tong, Z., Yang, Z., Patel, S., Chen, H., Gibbs, D., Yang, X., Hau, V. S., Kaminoh, Y., Harmon, J., Pearson, E., Buehler, J., Chen, Y., Yu, B., Tinkham, N. H., Zabriskie, N. A., Zeng, J., Luo, L., Sun, J. K., Prakash, M., Hamam, R. N., Tonna, S., Constantine, R., Ronquillo, C. C., Sadda, S., Avery, R. L., Brand, J. M., London, N., Anduze, A. L., King, G. L., Bernstein, P. S., Watkins, S., Genetics of Diabetes and Diabetic Complication Stu, , Jorde, L. B., Li, D. Y., Aiello, L. P., Pollak, M. R., Zhang, K.
(2008). Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl. Acad. Sci. USA
105: 6998-7003
[Abstract][Full Text]
Hos, D., Bock, F., Dietrich, T., Onderka, J., Kruse, F. E., Thierauch, K.-H., Cursiefen, C.
(2008). Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation. IOVS
49: 1836-1842
[Abstract][Full Text]
Bloomgarden, Z. T.
(2008). Diabetic Retinopathy. Diabetes Care
31: 1080-1083
[Full Text]
Pieh, C, Agostini, H, Buschbeck, C, Kruger, M, Schulte-Monting, J, Zirrgiebel, U, Drevs, J, Lagreze, W A
(2008). VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol
92: 689-693
[Abstract][Full Text]
Yu, L., Wu, X., Cheng, Z., Lee, C. V., LeCouter, J., Campa, C., Fuh, G., Lowman, H., Ferrara, N.
(2008). Interaction between Bevacizumab and Murine VEGF-A: A Reassessment. IOVS
49: 522-527
[Abstract][Full Text]
Kim, J. H., Kim, J. H., Yu, Y. S., Park, K. H., Kang, H. J., Lee, H.-Y., Kim, K.-W.
(2008). Antiangiogenic Effect of Deguelin on Choroidal Neovascularization. J. Pharmacol. Exp. Ther.
324: 643-647
[Abstract][Full Text]
Arevalo, J F, Maia, M, Flynn, H W Jr, Saravia, M, Avery, R L, Wu, L, Farah, M E., Pieramici, D J, Berrocal, M H, Sanchez, J G
(2008). Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol
92: 213-216
[Abstract][Full Text]
Lee, J.-H., Lee, W., Kwon, O. H., Kim, J.-H., Kwon, O. W., Kim, K. H., Lim, J.-B.
(2008). Cytokine Profile of Peripheral Blood in Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy. Annals of Clinical & Laboratory Science
38: 361-367
[Abstract][Full Text]
Itaya, M., Sakurai, E., Nozaki, M., Yamada, K., Yamasaki, S., Asai, K., Ogura, Y.
(2007). Upregulation of VEGF in Murine Retina via Monocyte Recruitment after Retinal Scatter Laser Photocoagulation. IOVS
48: 5677-5683
[Abstract][Full Text]
Ameri, H., Chader, G. J., Kim, J.-G., Sadda, S. R., Rao, N. A., Humayun, M. S.
(2007). The Effects of Intravitreous Bevacizumab on Retinal Neovascular Membrane and Normal Capillaries in Rabbits. IOVS
48: 5708-5715
[Abstract][Full Text]
Zayed, M. A., Yuan, W., Leisner, T. M., Chalothorn, D., McFadden, A. W., Schaller, M. D., Hartnett, M. E., Faber, J. E., Parise, L. V.
(2007). CIB1 Regulates Endothelial Cells and Ischemia-Induced Pathological and Adaptive Angiogenesis. Circ. Res.
101: 1185-1193
[Abstract][Full Text]
You, J.-J., Yang, C.-H., Huang, J.-S., Chen, M.-S., Yang, C.-M.
(2007). Fractalkine, a CX3C Chemokine, as a Mediator of Ocular Angiogenesis. IOVS
48: 5290-5298
[Abstract][Full Text]
Matsunaga, N., Chikaraishi, Y., Shimazawa, M., Yokota, S., Hara, H.
(2007). Vaccinium myrtillus (Bilberry) Extracts Reduce Angiogenesis In Vitro and In Vivo. Evid Based Complement Alternat Med
0: nem151v1-nem151
[Abstract][Full Text]
Sawada, O., Kawamura, H., Kakinoki, M., Sawada, T., Ohji, M.
(2007). Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy. Arch Ophthalmol
125: 1363-1366
[Abstract][Full Text]
Forooghian, F., Razavi, R., Timms, L.
(2007). Hypoxia-inducible factor expression in human RPE cells. Br J Ophthalmol
91: 1406-1410
[Abstract][Full Text]
Nishiguchi, K. M., Nakamura, M., Kaneko, H., Kachi, S., Terasaki, H.
(2007). The Role of VEGF and VEGFR2/Flk1 in Proliferation of Retinal Progenitor Cells in Murine Retinal Degeneration. IOVS
48: 4315-4320
[Abstract][Full Text]
Nagai, N., Izumi-Nagai, K., Oike, Y., Koto, T., Satofuka, S., Ozawa, Y., Yamashiro, K., Inoue, M., Tsubota, K., Umezawa, K., Ishida, S.
(2007). Suppression of Diabetes-Induced Retinal Inflammation by Blocking the Angiotensin II Type 1 Receptor or Its Downstream Nuclear Factor-{kappa}B Pathway. IOVS
48: 4342-4350
[Abstract][Full Text]
Cubbon, R. M, Rajwani, A., Wheatcroft, S. B
(2007). The impact of insulin resistance on endothelial function, progenitor cells and repair. Diabetes and Vascular Disease Research
4: 103-111
[Abstract]
Peters, S., Julien, S., Heiduschka, P., Grisanti, S., Ziemssen, F., Adler, M., Schraermeyer, U., Bartz-Schmidt, K.-U., the Tuebingen Bevacizumab Study Group,
(2007). Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol
91: 827-831
[Abstract][Full Text]
Abu El-Asrar, A. M, Missotten, L., Geboes, K.
(2007). Expression of hypoxia-inducible factor-1{alpha} and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol
91: 822-826
[Abstract][Full Text]
McLeod, D.
(2007). A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage. Br J Ophthalmol
91: 677-689
[Abstract][Full Text]
Nishikiori, N., Osanai, M., Chiba, H., Kojima, T., Mitamura, Y., Ohguro, H., Sawada, N.
(2007). Glial Cell-Derived Cytokines Attenuate the Breakdown of Vascular Integrity in Diabetic Retinopathy. Diabetes
56: 1333-1340
[Abstract][Full Text]
Lu, K., Zhou, Y., Kaufman, K., Mott, R., Ma, J.-x.
(2007). Rat strain-dependent susceptibility to ischemia-induced retinopathy associated with retinal vascular endothelial growth factor regulation. J Mol Endocrinol
38: 423-432
[Abstract][Full Text]
Inan, U. U., Avci, B., Kusbeci, T., Kaderli, B., Avci, R., Temel, S. G.
(2007). Preclinical Safety Evaluation of Intravitreal Injection of Full-Length Humanized Vascular Endothelial Growth Factor Antibody in Rabbit Eyes. IOVS
48: 1773-1781
[Abstract][Full Text]
Yokoi, M., Yamagishi, S.-i., Takeuchi, M., Matsui, T., Yoshida, Y., Ohgami, K., Amano-Okamoto, T., Ohno, S.
(2007). Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Br J Ophthalmol
91: 397-398
[Full Text]
Arroyo, J. G
(2007). Towards a rational approach to combination therapy for neovascular age-related macular degeneration. Br J Ophthalmol
91: 130-131
[Full Text]
Idris, I., Donnelly, R.
(2006). Protein kinase C {beta} inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diabetes and Vascular Disease Research
3: 172-178
[Abstract]
Murakami, T., Suzuma, K., Takagi, H., Kita, M., Ohashi, H., Watanabe, D., Ojima, T., Kurimoto, M., Kimura, T., Sakamoto, A., Unoki, N., Yoshimura, N.
(2006). Time-Lapse Imaging of Vitreoretinal Angiogenesis Originating from Both Quiescent and Mature Vessels in a Novel Ex Vivo System. IOVS
47: 5529-5536
[Abstract][Full Text]
Bhisitkul, R B
(2006). Vascular endothelial growth factor biology: clinical implications for ocular treatments.. Br J Ophthalmol
90: 1542-1547
[Abstract][Full Text]
Hartnett, M. E., Martiniuk, D. J., Saito, Y., Geisen, P., Peterson, L. J., McColm, J. R.
(2006). Triamcinolone Reduces Neovascularization, Capillary Density and IGF-1 Receptor Phosphorylation in a Model of Oxygen-Induced Retinopathy. IOVS
47: 4975-4982
[Abstract][Full Text]
Maines, L. W., French, K. J., Wolpert, E. B., Antonetti, D. A., Smith, C. D.
(2006). Pharmacologic Manipulation of Sphingosine Kinase in Retinal Endothelial Cells: Implications for Angiogenic Ocular Diseases. IOVS
47: 5022-5031
[Abstract][Full Text]
Harhaj, N. S., Felinski, E. A., Wolpert, E. B., Sundstrom, J. M., Gardner, T. W., Antonetti, D. A.
(2006). VEGF Activation of Protein Kinase C Stimulates Occludin Phosphorylation and Contributes to Endothelial Permeability. IOVS
47: 5106-5115
[Abstract][Full Text]
Yamagata, M., Rook, S. L., Sassa, Y., Ma, R. C., Geraldes, P., Goddard, L., Clermont, A., Gao, B., Salti, H., Gundel, R., White, M., Feener, E. P., Aiello, L. P., King, G. L.
(2006). Bactericidal/permeability-increasing protein's signaling pathways and its retinal trophic and anti-angiogenic effects. FASEB J.
20: 2058-2067
[Abstract][Full Text]
Missotten, G. S. O., Notting, I. C., Schlingemann, R. O., Zijlmans, H. J., Lau, C., Eilers, P. H. C., Keunen, J. E. E., Jager, M. J.
(2006). Vascular Endothelial Growth Factor A in Eyes With Uveal Melanoma. Arch Ophthalmol
124: 1428-1434
[Abstract][Full Text]
Kuiper, E. J., de Smet, M. D., van Meurs, J. C., Tan, H. S., Tanck, M. W. T., Oliver, N., van Nieuwenhoven, F. A., Goldschmeding, R., Schlingemann, R. O.
(2006). Association of Connective Tissue Growth Factor With Fibrosis in Vitreoretinal Disorders in the Human Eye. Arch Ophthalmol
124: 1457-1462
[Abstract][Full Text]
Zhang, S. X, Wang, J. J, Gao, G., Parke, K., Ma, J.-x.
(2006). Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy.. J Mol Endocrinol
37: 1-12
[Abstract][Full Text]
Beharry, K. D. A., Modanlou, H. D., Hasan, J., Gharraee, Z., Abad-Santos, P., Sills, J. H., Jan, A., Nageotte, S., Aranda, J. V.
(2006). Comparative Effects of Early Postnatal Ibuprofen and Indomethacin on VEGF, IGF-I, and GH during Rat Ocular Development.. IOVS
47: 3036-3043
[Abstract][Full Text]
Neu, J., Afzal, A., Pan, H., Gallego, E., Li, N., Calzi, S. L., Caballero, S., Spoerri, P. E., Shaw, L. C., Grant, M. B.
(2006). The dipeptide arg-gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy.. IOVS
47: 3151-3155
[Abstract][Full Text]
Chapman, J. A, Beckey, C.
(2006). Pegaptanib: A Novel Approach to Ocular Neovascularization. The Annals of Pharmacotherapy
40: 1322-1326
[Abstract][Full Text]
Masuzawa, K., Jesmin, S., Maeda, S., Zaedi, S., Shimojo, N., Miyauchi, T., Goto, K.
(2006). Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina.. Exp. Biol. Med.
231: 1090-1094
[Abstract][Full Text]
Shaw, S. G., Boden, J. P., Biecker, E., Reichen, J., Rothen, B.
(2006). Endothelin Antagonism Prevents Diabetic Retinopathy in NOD Mice: A Potential Role of the Angiogenic Factor Adrenomedullin.. Exp. Biol. Med.
231: 1101-1105
[Abstract][Full Text]
Patel, J I, Hykin, P G, Cree, I A
(2006). Diabetic cataract removal: postoperative progression of maculopathy--growth factor and clinical analysis. Br J Ophthalmol
90: 697-701
[Abstract][Full Text]
Amrite, A. C., Ayalasomayajula, S. P., Cheruvu, N. P. S., Kompella, U. B.
(2006). Single Periocular Injection of Celecoxib-PLGA Microparticles Inhibits Diabetes-Induced Elevations in Retinal PGE2, VEGF, and Vascular Leakage.. IOVS
47: 1149-1160
[Abstract][Full Text]
Modanlou, H. D., Gharraee, Z., Hasan, J., Waltzman, J., Nageotte, S., Beharry, K. D. A.
(2006). Ontogeny of VEGF, IGF-I, and GH in Neonatal Rat Serum, Vitreous Fluid, and Retina from Birth to Weaning. IOVS
47: 738-744
[Abstract][Full Text]
Aiello, L. P., Clermont, A., Arora, V., Davis, M. D., Sheetz, M. J., Bursell, S.-E.
(2006). Inhibition of PKC {beta} by Oral Administration of Ruboxistaurin Is Well Tolerated and Ameliorates Diabetes-Induced Retinal Hemodynamic Abnormalities in Patients. IOVS
47: 86-92
[Abstract][Full Text]
Wiley, L. A., Berkowitz, B. A., Steinle, J. J.
(2006). Superior Cervical Ganglionectomy Induces Changes in Growth Factor Expression in the Rat Retina. IOVS
47: 439-443
[Abstract][Full Text]
Ojima, T., Takagi, H., Suzuma, K., Oh, H., Suzuma, I., Ohashi, H., Watanabe, D., Suganami, E., Murakami, T., Kurimoto, M., Honda, Y., Yoshimura, N.
(2006). EphrinA1 Inhibits Vascular Endothelial Growth Factor-Induced Intracellular Signaling and Suppresses Retinal Neovascularization and Blood-Retinal Barrier Breakdown. Am. J. Pathol.
168: 331-339
[Abstract][Full Text]
Yoo, M. H., Hyun, H.-J., Koh, J.-Y., Yoon, Y. H.
(2005). Riluzole Inhibits VEGF-Induced Endothelial Cell Proliferation In Vitro and Hyperoxia-Induced Abnormal Vessel Formation In Vivo. IOVS
46: 4780-4787
[Abstract][Full Text]
Akiyama, H., Mohamedali, K. A., e Silva, R. L., Kachi, S., Shen, J., Hatara, C., Umeda, N., Hackett, S. F., Aslam, S., Krause, M., Lai, H., Rosenblum, M. G., Campochiaro, P. A.
(2005). Vascular Targeting of Ocular Neovascularization with a Vascular Endothelial Growth Factor121/Gelonin Chimeric Protein. Mol. Pharmacol.
68: 1543-1550
[Abstract][Full Text]
Chen, W., Esselman, W. J., Jump, D. B., Busik, J. V.
(2005). Anti-inflammatory Effect of Docosahexaenoic Acid on Cytokine-Induced Adhesion Molecule Expression in Human Retinal Vascular Endothelial Cells. IOVS
46: 4342-4347
[Abstract][Full Text]
Yamada, N., Horikawa, Y., Oda, N., Iizuka, K., Shihara, N., Kishi, S., Takeda, J.
(2005). Genetic Variation in the Hypoxia-Inducible Factor-1{alpha} Gene Is Associated with Type 2 Diabetes in Japanese. J. Clin. Endocrinol. Metab.
90: 5841-5847
[Abstract][Full Text]
Silva, R. L. e, Saishin, Y., Saishin, Y., Akiyama, H., Kachi, S., Aslam, S., Rogers, B., Deering, T., Gong, Y. Y., Hackett, S. F., Lai, H., Frydman, B. J., Valasinas, A., Marton, L. J., Campochiaro, P. A.
(2005). Suppression and Regression of Choroidal Neovascularization by Polyamine Analogues. IOVS
46: 3323-3330
[Abstract][Full Text]
Watanabe, D., Suzuma, K., Matsui, S., Kurimoto, M., Kiryu, J., Kita, M., Suzuma, I., Ohashi, H., Ojima, T., Murakami, T., Kobayashi, T., Masuda, S., Nagao, M., Yoshimura, N., Takagi, H.
(2005). Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy. NEJM
353: 782-792
[Abstract][Full Text]
Aiello, L. P.
(2005). Angiogenic Pathways in Diabetic Retinopathy. NEJM
353: 839-841
[Full Text]
Barile, G. R., Pachydaki, S. I., Tari, S. R., Lee, S. E., Donmoyer, C. M., Ma, W., Rong, L. L., Buciarelli, L. G., Wendt, T., Horig, H., Hudson, B. I., Qu, W., Weinberg, A. D., Yan, S. F., Schmidt, A. M.
(2005). The RAGE Axis in Early Diabetic Retinopathy. IOVS
46: 2916-2924
[Abstract][Full Text]
Laham, R. J., Post, M., Rezaee, M., Donnell-Fink, L., Wykrzykowska, J. J., Lee, S. U., Baim, D. S., Sellke, F. W.
(2005). TRANSENDOCARDIAL AND TRANSEPICARDIAL INTRAMYOCARDIAL FIBROBLAST GROWTH FACTOR-2 ADMINISTRATION: MYOCARDIAL AND TISSUE DISTRIBUTION. Drug Metab. Dispos.
33: 1101-1107
[Abstract][Full Text]
Ashraf, A., Mick, G., Meleth, S., Abdullatif, H., Wang, X., McCormick, K.
(2005). Effect of Insulin on Plasma Vascular Endothelial Growth Factor in Children with New-Onset Diabetes. J. Clin. Endocrinol. Metab.
90: 4920-4923
[Abstract][Full Text]
The PKC-DRS Study Group,
(2005). The Effect of Ruboxistaurin on Visual Loss in Patients With Moderately Severe to Very Severe Nonproliferative Diabetic Retinopathy: Initial Results of the Protein Kinase C {beta} Inhibitor Diabetic Retinopathy Study (PKC-DRS) Multicenter Randomized Clinical Trial. Diabetes
54: 2188-2197
[Abstract][Full Text]
Mohan, J S, Lip, P L, Blann, A D, Bareford, D, Lip, G Y H
(2005). The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of laser treatment. Br J Ophthalmol
89: 815-819
[Abstract][Full Text]
Yokoi, M, Yamagishi, S-i, Takeuchi, M, Ohgami, K, Okamoto, T, Saito, W, Muramatsu, M, Imaizumi, T, Ohno, S
(2005). Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol
89: 673-675
[Abstract][Full Text]
Miyazawa-Hoshimoto, S., Takahashi, K., Bujo, H., Hashimoto, N., Yagui, K., Saito, Y.
(2005). Roles of degree of fat deposition and its localization on VEGF expression in adipocytes. Am. J. Physiol. Endocrinol. Metab.
288: E1128-E1136
[Abstract][Full Text]
Krady, J. K., Basu, A., Allen, C. M., Xu, Y., LaNoue, K. F., Gardner, T. W., Levison, S. W.
(2005). Minocycline Reduces Proinflammatory Cytokine Expression, Microglial Activation, and Caspase-3 Activation in a Rodent Model of Diabetic Retinopathy. Diabetes
54: 1559-1565
[Abstract][Full Text]
Lebherz, C., Maguire, A. M., Auricchio, A., Tang, W., Aleman, T. S., Wei, Z., Grant, R., Cideciyan, A. V., Jacobson, S. G., Wilson, J. M., Bennett, J.
(2005). Nonhuman Primate Models for Diabetic Ocular Neovascularization Using AAV2-Mediated Overexpression of Vascular Endothelial Growth Factor. Diabetes
54: 1141-1149
[Abstract][Full Text]
Patel, J I, Hykin, P G, Gregor, Z J, Boulton, M, Cree, I A
(2005). Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol
89: 480-483
[Abstract][Full Text]
Simons, M.
(2005). Angiogenesis: Where Do We Stand Now?. Circulation
111: 1556-1566
[Full Text]
van Wijngaarden, P., Coster, D. J., Williams, K. A.
(2005). Inhibitors of Ocular Neovascularization: Promises and Potential Problems. JAMA
293: 1509-1513
[Full Text]
Yang, W. J., Yang, D. D., Na, S., Sandusky, G. E., Zhang, Q., Zhao, G.
(2005). Dicer Is Required for Embryonic Angiogenesis during Mouse Development. J. Biol. Chem.
280: 9330-9335
[Abstract][Full Text]
Stitt, A. W., McGoldrick, C., Rice-McCaldin, A., McCance, D. R., Glenn, J. V., Hsu, D. K., Liu, F.-T., Thorpe, S. R., Gardiner, T. A.
(2005). Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3. Diabetes
54: 785-794
[Abstract][Full Text]
Feliers, D., Duraisamy, S., Barnes, J. L., Ghosh-Choudhury, G., Kasinath, B. S.
(2005). Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II. Am. J. Physiol. Renal Physiol.
288: F521-F529
[Abstract][Full Text]
1 heavy-chain clone,26 as described by Park et al27. The chimeric receptor has the same affinity for VEGF as does the full-length VEGF receptor. The sensitivity and variability of this assay were similar to those of the radioimmunoassay. 
0.05. 
Previous
